Artrya signs US$0.5M hospital agreement
- Artrya signed a five-year agreement with Huntsville Hospital Health System with a minimum contracted value of US$0.5 million.
- The agreement marks the company's first conversion of an SAPPHIRE study participant into a commercial customer.
- The deal expands Artrya's commercial footprint in the United States from three to four healthcare providers.
Artrya (ASX:AYA) executed a five-year commercial agreement with Huntsville Hospital Health System featuring a minimum contracted value of US$0.5 million.
The contract expands the medical technology company's client base following previous agreements with Tanner Health, Northeast Georgia Health System, and Cone Health.
“The conversion of HH Health from an SAPPHIRE study participant into a commercial customer is an important milestone for Artrya’s U.S. strategy,” said Artrya co-founder and CEO John Konstantopoulos.
The software agreement covers 15 hospitals across HH Health's regional network and adds recurring software-as-a-service earnings from the Salix Coronary Anatomy module alongside fee-per-scan revenue from additional modules.
Artrya stated that the deal validates its strategy of converting clinical research relationships into long-term commercial customer accounts.
Following the announcement, the Artrya share price was unchanged at $3.89.
The company develops and commercialises an artificial intelligence cloud platform designed to assist clinicians with the real-time, point-of-care assessment of coronary artery disease.
Its strategy focuses on securing regulatory approvals and commercialising its Salix technology suite across high-volume cardiovascular centres in the United States.
